Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly D Moynihan

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cancer Cell|April 16, 2015
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2Eric F Zhu, Shuning A Gai, Cary F Opel, et al.
Science Immunology|July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 sheddingLawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.
Cancer Discovery|April 2, 2024
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor ImmunityKelly D Moynihan, Manu P Kumar, Hussein Sultan, et al.
Cancer Immunology Research|March 15, 2023
Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I ExpressionZachariah P Tritz, Katayoun Ayasoufi, Delaney M Wolf, et al.
Frontiers in Immunology|July 11, 2022
Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine MelanomaBeth E Grace, Coralie M Backlund, Duncan M Morgan, et al.
Nature Medicine|November 8, 2016
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesKelly D Moynihan, Cary F Opel, Gregory L Szeto, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer Cell|April 16, 2015
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2Eric F Zhu, Shuning A Gai, Cary F Opel, et al.
Science Immunology|July 19, 2020
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 sheddingLawrence P Andrews, Ashwin Somasundaram, Jessica M Moskovitz, et al.
Cancer Discovery|April 2, 2024
IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor ImmunityKelly D Moynihan, Manu P Kumar, Hussein Sultan, et al.
Cancer Immunology Research|March 15, 2023
Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I ExpressionZachariah P Tritz, Katayoun Ayasoufi, Delaney M Wolf, et al.
Frontiers in Immunology|July 11, 2022
Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine MelanomaBeth E Grace, Coralie M Backlund, Duncan M Morgan, et al.
Nature Medicine|November 8, 2016
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responsesKelly D Moynihan, Cary F Opel, Gregory L Szeto, et al.
Nature|July 24, 2024
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapyHussein Sultan, Yoshiko Takeuchi, Jeffrey P Ward, et al.
Nature Cancer|July 10, 2023
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancerInes Mota, Enrico Patrucco, Cristina Mastini, et al.
Pageof 3